Our analysis of human tumor samples confirmed that loss of p53 pathway activity was strongly correlated with WGD, including in tumors that harbor BRAF mutations and other mutations that activate RAS/MAPK signaling (Supplementary Fig. 8). This evidence concerns the gene TP53 and neoplasm.